1-15 of 15
Patrick Hlavacek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W. LeBlanc, Joseph C. Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez-Cruz, Patrick Hlavacek
Journal: Blood
Blood (2024) 144 (Supplement 1): 7028.
https://doi.org/10.1182/blood-2024-206856
Published: 2024
Journal Articles

An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Luciano J. Costa, Thomas W. LeBlanc, Hans Tesch, Pieter Sonneveld, Sarasa M.A. Johnson, Francis Vekeman, Patrick Hlavacek, Aster Meche, Paul Cislo, David Hughes, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2024) 144 (Supplement 1): 2401.
https://doi.org/10.1182/blood-2024-203920
Published: 2024
Journal Articles

Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W. LeBlanc, Joseph C. Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez-Cruz, Patrick Hlavacek
Journal: Blood
Blood (2024) 144 (Supplement 1): 3367.
https://doi.org/10.1182/blood-2024-206951
Published: 2024
Journal Articles

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study - Interim Results

Charis Charalampous, Shaji Kumar, Ricardo D. Parrondo, Saurabh Chhabra, Madhu Nagaraj, Mei Sheng Duh, Priyanka J. Bobbili, Aolin Wang, Jingyi Chen, Manasi Mohan, Patrick Hlavacek, Rickard Sandin, Joseph C. Cappelleri, David Hughes, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2024) 144 (Supplement 1): 3770.
https://doi.org/10.1182/blood-2024-204005
Published: 2024
Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab and Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek
Journal: Blood
Blood (2023) 142 (Supplement 1): 2015.
https://doi.org/10.1182/blood-2023-186409
Published: 2023
Journal Articles

Multiple Myeloma Treatment-Related Decision-Making and Preferences of Patients and Care Partners in the United States

Darcy R Flora, Rachel Byrd, Daniel Platt, Patrick Hlavacek, Erinn Hoag Goldman, Joseph C Cappelleri, C Todd Kennedy, Thomas W LeBlanc
Journal: Blood
Blood (2023) 142 (Supplement 1): 7357.
https://doi.org/10.1182/blood-2023-180951
Published: 2023
Journal Articles

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study

Charalampos Charalampous, Shaji Kunnathu Kumar, Ricardo Parrondo, Saurabh Chhabra, Mei Sheng Duh, Priyanka Bobbili, Aolin Wang, Jingyi Chen, Manasi Mohan, Patrick Hlavacek, Jinma Ren, Alex Schepart, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2023) 142 (Supplement 1): 6727.
https://doi.org/10.1182/blood-2023-180984
Published: 2023
Journal Articles

An Indirect Comparison of Elranatamab's Progression-Free Survival and Overall Survival from Magnetismm-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Luciano Costa, Thomas W LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2023) 142 (Supplement 1): 6716.
https://doi.org/10.1182/blood-2023-180848
Published: 2023
Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment Among Patients with Triple-Class Exposed/Refractory Multiple Myeloma in Canada

Isha Mol, Yannan Hu, Fiorella Fanton-Aita, Phu Vinh On, Hicham Gonzalez, Richard LeBlanc, Donna Reece, Jiandong Su, Engin Gul, Alissa Visram, Joseph C Cappelleri, Haitao Chu, Guido Nador, Patrick Hlavacek
Journal: Blood
Blood (2023) 142 (Supplement 1): 6738.
https://doi.org/10.1182/blood-2023-186559
Published: 2023
Journal Articles

Changing Care Journey for Patients with Multiple Myeloma in the United States

Darcy R Flora, Rachel Byrd, Daniel Platt, Patrick Hlavacek, Erinn Hoag Goldman, Joseph C Cappelleri, C Todd Kennedy, Thomas W LeBlanc
Journal: Blood
Blood (2023) 142 (Supplement 1): 7383.
https://doi.org/10.1182/blood-2023-179554
Published: 2023
Journal Articles

A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab Versus Physician's Choice of Treatment in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Alex Schepart, Patrick Hlavacek
Journal: Blood
Blood (2023) 142 (Supplement 1): 6731.
https://doi.org/10.1182/blood-2023-185920
Published: 2023
Journal Articles

Effectiveness and Safety of Apixaban Vs Warfarin Among Venous Thromboembolism Patients Using Five US Databases: A Subgroup Analysis of Obesity

Alexander T Cohen, MBBS MSc MDFRACP FESC, Janvi Sah, MS, Theodore Lee, MD, Gail Wygant, RN, Lisa Rosenblatt, MD MPH, Patrick Hlavacek, MPH, Birol Emir, PhD, Allison Keshishian, MPH, Rachel Delinger, MPH, Xuemei Luo, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1.
https://doi.org/10.1182/blood-2020-140453
Published: 2020
Journal Articles

Differences in Admission Rates Among Patients Treated with Apixaban Vs. Warfarin for Venous Thromboembolism in the Emergency Department

Steven Deitelzweig, MD, Patrick Hlavacek, MPH, Jack Mardekian, PhD, Lisa Rosenblatt, MD MPH, Cristina Russ, MD PhD, Kenneth Tuell, RPh, Melissa Lingohr-Smith, PhD, Jay Lin, PhD MBA, Jennifer D Guo, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2157.
https://doi.org/10.1182/blood-2019-125845
Published: 2019
Journal Articles

Safety and Effectiveness of Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients with Active Cancer: A Retrospective Analysis Using Four US Claims Databases

Alexander T Cohen, MBBS, MSc, MD, Allison Keshishian, Theodore Lee, MD, Gail Wygant, RN, MS, Lisa Rosenblatt, MD MPH, Patrick Hlavacek, MPH, Jack Mardekian, PhD, Daniel Wiederkehr, MPH, Janvi Sah, MS, Xuemei Luo, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 326.
https://doi.org/10.1182/blood-2019-121769
Published: 2019
Journal Articles

Safety and Effectiveness of Apixaban, LMWH and Warfarin Among Venous Thromboembolism (VTE) Patients with Active Cancer: A Subgroup Analysis of VTE Risk Scale

Alexander T Cohen, MBBS, MSc, MD, Allison Keshishian, Theodore Lee, MD, Gail Wygant, RN, MS, Lisa Rosenblatt, MD MPH, Patrick Hlavacek, MPH, Jack Mardekian, PhD, Daniel Wiederkehr, MPH, Janvi Sah, MS, Xuemei Luo, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 327.
https://doi.org/10.1182/blood-2019-126931
Published: 2019